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INTRODUCTION
Lung cancer became the leading cause of cancer death in
the world; however, even the early stage does not have a sat-
isfactory long-term survival rate after complete resection. Dur-
ing follow-up after surgical resection in our center, we noted
a possible difference in recurrence patterns between squamous
cell carcinoma and non-squamous cell carcinoma. After resec-
tion of non-small cell lung cancer, histologic type is noted as
a prognostic factor in some reports, but not in others. Recently,
some studies have reported on the prognostic significance of
several biological factors in the early stage of non-small cell
lung cancer (1, 2). Histologic characterization offers a starting
point for the analysis of biological prognostic factors. The aim
of the present study was to evaluate the pattern of recurrence
after curative resection of pathological stage I and II non-small
cell lung cancers, with special attention to the cell type.
MATERIALS AND METHODS
We reviewed the clinical records of 525 patients operated
on for pathologic stage I and II lung cancer between January
1995 and December 2000. Four hundred and forty-seven
lobectomies, 75 pneumonectomies, and 3 wedge resections
were performed. Eighteen patients with in-hospital mortality,
including operative mortality, were excluded. Another 25
patients were also excluded because they had carcinoid tumor,
or mucoepidermoid carcinoma. Clinicopathologic character-
istics of the remaining 482 patients are described in Table 1.
We obtained follow-up data by chest CT at 3 month intervals
for the first 2 yr and at 6 month intervals after 2 yr. Recurrence
was evaluated with our hospital records and information from
other hospitals. Recurrence pattern was classified into two
categories: locoregional and distant metastasis. Locoregional
recurrence included cancer development to supraclavicular
nodes, mediastinal nodes, pleural effusion or seeding, bronchial
stump and ipsilateral lung. Distant metastasis categorized
metastasis to contralateral lung, brain, bone, liver, adrenal
and other organs. Simultaneous locoregional and distant metas-
tasis was considered distant metastasis group.
Sex, pathological stage, tumor differentiation (well, mod-
erate, poor), extent of resection (wedge resection, lobectomy
including sleeve resection, and pneumonectomy), and histo-
logic type (squamous cell carcinoma, nonsquamous carcinoma
including adenocarcinoma and large cell carcinoma) were eval-
uated by univariate and multivariate analysis. Survival rates
were calculated by the actuarial method and compared by the
log-rank test with SPSS software.
RESULTS
Median follow-up period was 40 months (2-99 months)
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Pattern of Recurrence after Curative Resection of Local (Stage I and II)
Non-Small Cell Lung Cancer: Difference According to the Histologic Type
The aim of the present study was to evaluate the pattern of recurrence after com-
plete resection of pathological stage I, II non-small cell lung cancer, especially accord-
ing to the cell type. We reviewed the clinical records of 525 patients operated on for
pathologic stage I and II lung cancer. The histologic type was found to be squamous
in 253 and non-squamous in 229 patients. Median follow-up period was 40 months.
Recurrences were identified in 173 (36%) of 482 enrolled patients; distant metasta-
sis in 70%, distant and local recurrence in 11%, and local recurrence in 19%. Dis-
tant metastasis was more common in non-squamous than in squamous cell carci-
noma (p=0.044). Brain metastasis was more frequently identified in non-squamous
than in squamous cell carcinoma (24.2% vs. 7.3%. p=0.005). Multivariate analyses
showed that cell type is the significant risk factor for recurrence-free survival in stage
I and stage II non-small cell lung cancer. Recurrence-free survival curves showed
that non-squamous cell carcinoma had similar risks during early periods of follow-up
and more risks after 2 yr from the operation compared to squamous cell carcinoma.
Pathological stage and histologic type significantly influence recurrence-free survival.
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after operation. Recurrences were identified in 173 (36%) of
482 patients during follow-up; distant metastasis 70%, simul-
taneous distant metastasis and local recurrence 11%, and local
recurrence 19%. Distant metastasis was more common in non-
squamous cell carcinoma (adenocarcinoma and large cell car-
cinoma) than in squamous cell carcinoma (p=0.044). Brain
metastasis was found more frequently in non-squamous cell
carcinoma than in squamous carcinoma (24.2% vs. 7.3%. p=
0.005). There were no significant differences between local
and distant recurrences, according to either stage I or stage
II (p=0.382). Overall actuarial 5-yr survival rates for stage I
and stage II were 74% and 42% (p<0.001), respectively. Over-
all 5-yr recurrence-free survival rates were also statistically dif-
ferent (stage I, 57% and stage II, 36%, p<0.001). Univariate
analyses of recurrence-free survival in stage I and stage II are
described in Table 2. Multivariate analyses by the Cox regres-
sion test showed that cell type is the significant risk factor for
recurrence-free survival in both stage I and stage II non-small
cell lung cancer (Table 3). Recurrence-free survival curves show-
ed similar risks during early periods of follow-up for non-squamous
cell carcinoma, and more risks after 2 yr from the operation
when compared to squamous cell carcinoma (Fig. 1, 2).
DISCUSSION
We were fortunate to obtain nearly complete follow-up of
patients after surgical resection for local non-small cell lung
Variable
Stage I
SqC Non-SqC p
Stage II
SqC Non-SqC p
Age (yr)
≤60 61 85 0.069 40 19 0.725
>60 109 100 43 25
Sex
Male 160 96 0.001 81 25 0.001
Female 10 89 2 19
Differentiation
Well 27 38 0.003 14 10 0.161
Moderate 96 49 47 13
Poor 29 24 14 7
Extent of resection
Lobectomy 150 175 0.010 52 38 0.007
Pneumonectomy 20 8 30 6
Adjuvant therapy
None 154 177 0.056 46 32 0.057
Done 16 8 37 12
Table 1. Clinicopathological characteristics of 355 stage I and
127 stage II patients
SqC, squamous cell carcinoma.
Stage I
5-yr survival p 5-yr RFS p
Variable
Stage II
5-yr survival p 5-yr RFS p
Sex
Male 69% 0.0078 55% 0.0959 39% 0.1900 36% 0.8626
Female 84% 65% 58% 33%
Differentiation
Well 79% 0.1843 64% 0.0285 52% 0.3020 34% 0.6317
Moderate 68% 52% 42% 39%
Poor 72% 52% 34% 38%
Extent of resection
Lobectomy 76% 0.0233 58% 0.9178 44% 0.5610 35% 0.7481
Pneumonectomy 53% 54% 39% 40%
Adjuvant therapy
None 75% 0.0822 57% 0.7061 46% 0.5907 39% 0.4472
Done 53% 57% 36% 30%
Cell type
Squamous 72% 0.6226 60% 0.2189 43% 0.5326 42% 0.1191
Non-Squamous 76% 55% 41% 23%
Table 2. Univariate analyses of recurrence-free survival
RFS, recurrence-free survival.
Variable
Stage I
Odds
ratio
95% CI p
Stage I
Odds
ratio
95% CI p
Sex
Male/female 1.47 0.85-2.56 0.168 1.88 0.79-4.47 0.155
Differentiation
Moderate/well 1.94 1.10-3.42 0.022 1.21 0.61-2.40 0.577
Poor/well 2.07 1.09-3.96 0.027 1.35 0.56-3.25 0.502
Type of operation
Pneumonectomy/ 1.02 0.46-2.26 0.956 1.20 0.63-2.29 0.572
lobectomy
Adjuvant therapy
None/done 0.83 0.43-1.62 0.829 0.75 0.45-1.27 0.751
Cell type
Non-SqC/SqC 1.64 1.04-2.57 0.033 2.49 1.30-4.77 0.006
Table 3. Multivariate correlates of recurrence-free survival
CI, confidence interval; SqC, squamous cell carcinoma.676 Y.S. Choi, Y.M. Shim, K. Kim, et al.
cancer. Our study was initiated based on our initial observa-
tions that recurrence patterns appeared to be different, accord-
ing to the histology at outpatient follow-up. According to
previous reports, the histologic type of the tumor is one of
the determinants of survival in patients with resected local
non-small cell lung cancer. In the Lung Cancer Study Group,
cancer recurrences and cancer-related death were more fre-
quent and recurrence rates were higher in patients with non-
squamous histology (3). However, Martini et al. reported that
there was no difference in overall survival between squamous
and non-squamous cancers (4). Ramacciato et al. also reported
that histologic type did not play a statistically significant role
in the total incidence of recurrence (5). Rena et al. reported
better 5-yr survival rates for adenocarcinoma than for squa-
mous cell carcinoma (6). Our data demonstrated similar results
to those of the Lung Cancer Study Group. Recent data report-
ed by Okada et al. demonstrated that advanced stage, high
involvement of lymph nodes, male gender, and non-squamous
cancer were independent, unfavorable prognostic factors in
completely-resected lung cancer patients (7). We confirmed
that the poor prognosis of non-squamous cell carcinoma be-
comes evident after 2 yr. This finding could be explained by
the fact that distant metastases were more common in non-
squamous cell tumors than in the squamous type.
Our data also demonstrated that brain metastases were more
common in non-squamous carcinoma than in squamous cell
carcinoma, and some reports and preceding report by our insti-
tute showed corresponding results to ours (8-10). Whether
the patients benefit from the therapy for single brain metas-
tases remains another issue for study.
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Fig. 1. Recurrence-free survival according to the cell type in stage I
patients.
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Fig. 2. Recurrence-free survival according to the cell type in stage II
patients.
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